Results 171 to 180 of about 53,113 (297)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis

, 2022
Takeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Satoru Kakizaki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada   +38 more
openalex   +1 more source

Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial [PDF]

, 2020
Hyeong Dong Yuk, Chang Wook Jeong, Cheol Kwak, Hyeon Chang Kim, Kyung Chul Moon, Ja Hyeon Ku   +5 more
openalex   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Zirconium Zr 89-labeled Atezolizumab [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon   +15 more
wiley   +1 more source

Adjuvant chemo-immunotherapy shows comparable efficacy among mismatch-repair-deficient and mismatch-repair-proficient stage III colon cancer: an exploratory, reconstructed individual patient-level data analysis. [PDF]

J Immunother Cancer
Chen YT, Wang R, Situ YT, Wang WF, Zhang W, Lin JZ, Peng J, Wang ZX.   +7 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion. [PDF]

J Immunother
Huang JP, Tsai CK, Hsieh PY, Chen SC.
europepmc   +1 more source

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis [PDF]

Hongfu Cai, Ling Fang, Jingwen Lin, Zhiwei Zheng   +3 more
openalex   +1 more source

Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients.

, 2022
Hyeyeong Kim, Jaekyung Cheon, Yeongjung Ha, Han Sang Kim, Chang Gon Kim, Il Hwan Kim, Chan Kim, Sanghoon Jung, Hong Jae Chon   +8 more
openalex   +2 more sources